T. Rowe Price Health Care ETF(TMED.US)

Company Encyclopedia

T. Rowe Price Health Care ETF

TMED.US

Shareholder

Ownership	%Owned	Share Chg	Report Date
No Data

News

Teva Pharmaceutical Industries Q4 Non-GAAP Earnings, Revenue Rise; 2026 Guidance Issued

marketscreener·Yesterday at 23:28

Novo Nordisk sued for allegedly monopolizing diabetes drug Victoza

Danish pharmaceutical company Novo Nordisk faces a class action lawsuit in New York for allegedly monopolizing its diabetes drug Victoza. The lawsuit, filed by Smith Drug, claims Novo used a "pay-for-delay" scheme with Teva Pharmaceutical to prevent cheaper generic versions from entering the market. The complaint states that Novo unlawfully delayed Teva's generic launch, which could have occurred in 2023. Smith Drug seeks unspecified monetary damages for Victoza purchasers. The case is registered as Smith Drug Co v. Novo Nordisk Inc in the U.S. District Court for the Eastern District of New York.

Reuters·01/24/2026 06:24

Assessing Teva (TEVA) Valuation As Guidance Driven Momentum Lifts Long Term Profit Expectations

Teva Pharmaceutical Industries (TEVA) has issued multi-year earnings guidance indicating flat to slightly lower revenues by 2026, but with higher operating profits and growth targets through 2030. The stock has seen a 67.07% return over 90 days and is currently trading at a 45% intrinsic discount. Analysts estimate a fair value of $35.32, suggesting the stock is undervalued. However, concerns remain regarding execution risks and a significant net debt load. The current P/E ratio of 50.9x raises questions about whether market sentiment is ahead of fundamentals.

Simplywall·01/23/2026 19:20